1. Psoriatic Arthritis

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US

3. Introduction

4. Patient Case 1

5. Importance of Treating Skin Psoriasis

6. CASPAR Criteria

7. Is Psoriasis a Precursor for PsA?

8. Patient Case 1 3 Years Later

9. Does the Patient Meet CASPAR Criteria?

10. Patient Case 1 (cont)

11. GRAPPA 2015 Guidelines

12. Patient Case 1 Treatment for Peripheral Arthritis Domain

13. Apremilast

14. Mild Joint Symptoms With Severe Skin Symptoms: A Look at IL-17 Inhibitors

15. What If Joint Symptoms Are Severe With 2% BSA Affected?

16. Patient Case 1 (cont)

17. Treatment Options for Enthesitis and Dactylitis: A Widened Toolbox

18. IL-17a Inhibitors

19. IL-12/23 Inhibitors

20. Patient Case 1 Conclusion

21. Patient Case 2

22. Use of Methotrexate as Monotherapy vs in Combination With TNF-α Inhibitors

23. Patient Case 2 Follow-Up and Treatment Plan

24. Shared Decision-Making

25. New and Emerging Therapies for the Treatment of PsA

26. Concluding Remarks